NEOPROCT

This brand name is authorized in Finland

Active ingredients

The drug NEOPROCT contains a combination of these active pharmaceutical ingredients (APIs):

1 Fluocortolone
UNII 9J8AL6K50Q - FLUOCORTOLONE PIVALATE

Fluocortolone pivalate inhibits inflammatory and allergic skin reactions, and alleviates subjective complaints such as pruritus, smarting, and pain. The substance reduces dilatation of the capillaries, oedema of the interstitial cells and infiltration of the tissues. Capillary multiplication is inhibited.

Read about Fluocortolone
2 Lidocaine
UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.

Read about Lidocaine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C05AA08 Fluocortolone C Cardiovascular system → C05 Vasoprotectives → C05A Agents for treatment of hemorrhoids and anal fissures for topical use → C05AA Corticosteroids
Discover more medicines within C05AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: FI Lรครคkealan turvallisuus- ja kehittรคmiskeskus Identifier(s): 155333, 155341, 155457

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.